Figure 3.

Combined treatment with EGCG plus FA effectively attenuates cerebral parenchymal and vascular β-amyloid deposits and lowers Aβ levels. A–C, quantitative image analysis of Aβ burden (%) from 4G8 immunostains is shown. D–F, morphometric analysis of cerebral parenchymal β-amyloid deposit size. Mean plaque size is shown from blind assignment to one of three mutually exclusive categories: small (<25 μm; D), medium (between 25 and 50 μm; E), or large (>50 μm; F). G, severity of cerebral amyloid angiopathy (mean CAA deposit number) is shown. A–C, each brain region is indicated on the x axis (RSC, H, and EC). D–F, mean deposit number is shown on the y axis, and brain region is denoted on the x axis. G, mean CAA number is shown on the y axis, and brain region is presented on the x axis. Data were obtained from APP/PS1 mice that received vehicle (APP/PS1-V, n = 8), EGCG (APP/PS1-EGCG, n = 8), FA (APP/PS1-FA, n = 8), or EGCG plus FA (APP/PS1-EGCG/FA, n = 8) for 3 months beginning at 12 months of age (mouse age at sacrifice = 15 months) for A–G in addition to 12-month-old untreated APP/PS1 mice (APP/PS1–12M, n = 8) for A–C. Data for A–G are presented as standard deviations of the means. Statistical comparisons for A–G are between-groups within each brain region. *, p < 0.05; **, p < 0.01; ***, p ≤ 0.001 for APP/PS1-V versus the other treated mice; †, p < 0.05; ††, p < 0.01 for APP/PS1-EGCG/FA versus APP/PS1-EGCG or APP/PS1-FA mice. V, vehicle.